FDA schedules public hearing on cannabis

Over the last decade, state and federal lawmakers have increasingly embraced a plant that was long denounced: cannabis. FDA's challenge is figuring out whether and how to regulate cannabis-containing products--including dietary supplements that contain CBD.

Josh Long, Associate editorial director, SupplySide Supplement Journal

April 2, 2019

3 Min Read
CBD oil 2019

FDA plans to hold a public hearing on May 31 in Silver Spring, Maryland to explore issues around products containing cannabis or cannabis-derived compounds such as cannabidiol (CBD).

The hearing is to gather “scientific data and information about the safety, manufacturing, product quality, marketing, labeling and sale of products containing cannabis or cannabis-derived compounds,” according to a notice scheduled to be published April 3 in the Federal Register.

Products regulated by FDA—including conventional food, cosmetics, drugs and supplements—are being marketed with varying amounts of CBD, a compound that derives from both hemp and marijuana and is said to promote myriad health benefits.

Over the last decade, state and federal lawmakers have increasingly embraced a plant that was long denounced: cannabis.

For example:

  • 33 states and Washington, D.C. authorize the use of medical marijuana and 14 other states have medical programs circumscribed to CBD products, according to FDA’s notice;
     

  • 10 states and Washington, D.C. have legalized marijuana for recreational use; and
     

  • In the 2018 Farm Bill (otherwise known as the Agricultural Improvement Act of 2018), Congress removed hemp from the Controlled Substances Act and treated it as an agricultural crop.

Marijuana remains illegal under federal law and despite passage of the Farm Bill, Congress preserved FDA’s ability to regulate cannabis-containing products under the Federal Food, Drug & Cosmetic Act (FD&C) and Public Health Service Act.

Based on its interpretation of the FD&C, FDA has long asserted CBD cannot be added to conventional food or sold in dietary supplements. The private sector has defied the agency, and hundreds of hemp-based CBD products have emerged in recent years.

“They spilled the wine on the table,” said Daniel Fabricant, Ph.D., president and CEO of the Natural Products Association (NPA). “The wine’s not getting back in the bottle.”

FDA is looking into a potential rulemaking that would allow CBD to be sold in conventional food and dietary supplements. Scott Gottlieb, M.D., the outgoing commissioner of FDA, has signaled his agency is willing to work with members of Congress on a legislative solution if FDA determines a rulemaking would be too onerous.

“The public hearing will give stakeholders an opportunity to provide the FDA with additional input relevant to the agency's regulatory strategy related to existing products, as well as the lawful pathways by which appropriate products containing cannabis or cannabis-derived compounds can be marketed, and how we can make these legal pathways more predictable and efficient,” Gottlieb said Tuesday in a statement. “We hope to gain additional information and data for the FDA to consider with respect to products containing cannabis and cannabis-derived compounds, including CBD.”

FDA also has formed a high-level working group within the agency to explore routes that would allow CBD in food and supplements to be lawfully marketed.

“I’m also asking the group to consider whether there are legislative options that might lead to more efficient and appropriate pathways than might be available under current law—again, with the same science-based, public health focus that the FDA endeavors to bring to all matters before it,” Gottlieb said.

The FDA group, Gottlieb noted, plans to begin sharing information and/or findings as early as summer 2019.

“This is a complicated topic and we expect that it could take some time to resolve fully,” said the commissioner, who is expected to leave his position April 5. “Nevertheless, we're deeply focused on this issue and committed to continuing to engage relevant stakeholders as we consider potential paths forward.”

About the Author

Josh Long

Associate editorial director, SupplySide Supplement Journal , Informa Markets Health and Nutrition

Josh Long directs the online news, feature and op-ed coverage at SupplySide Supplement Journal (formerly known as Natural Products Insider), which targets the health and wellness industry. He has been reporting on developments in the dietary supplement industry for over a decade, with a focus on regulatory issues, including at the Food and Drug Administration.

He has moderated and/or presented at industry trade shows, including SupplySide East, SupplySide West, Natural Products Expo West, NBJ Summit and the annual Dietary Supplement Regulatory Summit.

Connect with Josh on LinkedIn and ping him with story ideas at [email protected]

Education and previous experience

Josh majored in journalism and graduated from Arizona State University the same year "Jake the Snake" Plummer led the Sun Devils to the Rose Bowl against the Ohio State Buckeyes. He also holds a J.D. from the University of Wyoming College of Law, was admitted in 2008 to practice law in the state of Colorado and spent a year clerking for a state district court judge.

Over more than a quarter century, he’s written on various topics for newspapers and business-to-business publications – from the Yavapai in Arizona and a controversial plan for a nuclear-waste incinerator in Idaho to nuanced issues, including FDA enforcement of the Dietary Supplement Health and Education Act of 1994 (DSHEA).

Since the late 1990s, his articles have been published in a variety of media, including but not limited to, the Cape Cod Times (in Massachusetts), Sedona Red Rock News (in Arizona), Denver Post (in Colorado), Casper Star-Tribune (in Wyoming), now-defunct Jackson Hole Guide (in Wyoming), Colorado Lawyer (published by the Colorado Bar Association) and Nutrition Business Journal.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like